• Something wrong with this record ?

Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries

X. Li, J. Bilcke, AW. van der Velden, R. Bruyndonckx, S. Coenen, E. Bongard, M. de Paor, S. Chlabicz, M. Godycki-Cwirko, N. Francis, R. Aabenhus, HC. Bucher, A. Colliers, A. De Sutter, A. Garcia-Sangenis, D. Glinz, NJ. Harbin, K. Kosiek, M....

. 2023 ; 24 (6) : 909-922. [pub] 20220922

Language English Country Germany

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23010844

Grant support
grant HEALTH-F3-2013-602525 European Commission

BACKGROUND: Oseltamivir is usually not often prescribed (or reimbursed) for non-high-risk patients consulting for influenza-like-illness (ILI) in primary care in Europe. We aimed to evaluate the cost-effectiveness of adding oseltamivir to usual primary care in adults/adolescents (13 years +) and children with ILI during seasonal influenza epidemics, using data collected in an open-label, multi-season, randomised controlled trial of oseltamivir in 15 European countries. METHODS: Direct and indirect cost estimates were based on patient reported resource use and official country-specific unit costs. Health-Related Quality of Life was assessed by EQ-5D questionnaires. Costs and quality adjusted life-years (QALY) were bootstrapped (N = 10,000) to estimate incremental cost-effectiveness ratios (ICER), from both the healthcare payers' and the societal perspectives, with uncertainty expressed through probabilistic sensitivity analysis and expected value for perfect information (EVPI) analysis. Additionally, scenario (self-reported spending), comorbidities subgroup and country-specific analyses were performed. RESULTS: The healthcare payers' expected ICERs of oseltamivir were €22,459 per QALY gained in adults/adolescents and €13,001 in children. From the societal perspective, oseltamivir was cost-saving in adults/adolescents, but the ICER is €8,344 in children. Large uncertainties were observed in subgroups with comorbidities, especially for children. The expected ICERs and extent of decision uncertainty varied between countries (EVPI ranged €1-€35 per patient). CONCLUSION: Adding oseltamivir to primary usual care in Europe is likely to be cost-effective for treating adults/adolescents and children with ILI from the healthcare payers' perspective (if willingness-to-pay per QALY gained > €22,459) and cost-saving in adults/adolescents from a societal perspective.

Centre for Family and Community Medicine Medical University of Lodz Lodz Poland

Centre for Health Economics Research and Modelling Infectious Diseases University of Antwerp Campus Drie Eiken room D S 221 Universiteitsplein 1 2610 Antwerp Belgium

Département de Santé Publique Hôpital de l'Archet Nice France

Department of Clinical Research Basel Institute for Clinical Epidemiology and Biostatistics University Hospital Basel Basel Switzerland

Department of Family Medicine and Population Health University of Antwerp Antwerp Belgium

Department of Family Medicine Medical University of Bialystok Białystok Poland

Department of General Practice Antibiotic Center for Primary Care Institute of Health and Society University of Oslo Oslo Norway

Department of Public Health and Primary Care Gent University Gent Belgium

Division of Infectious Diseases and Hospital Hygiene Basel Institute for Clinical Epidemiology and Biostatistics University Hospital Basel Basel Switzerland

DRC Drug Research Center LLC Balatonfüred Hungary

Family Doctors' Clinic Lodz Poland

FDC Mano šeimos gydytojas Klaipeda Lithuania

General Practice and Primary Health Care at the School of Medicine University of Crete Crete Greece

General Practice Family Medicine School of Public Health and Community Medicine Institute of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg Sweden

Institute of General Practice 1st Faculty of Medicine Charles University Prague Prague Czech Republic

Interuniversity Institute for Biostatistics and Statistical Bioinformatics Hasselt University Hasselt Belgium

Julius Center for Health Sciences and Primary Care University Medical Center Utrecht The Netherlands

Laboratory of Medical Microbiology Vaccine and Infectious Disease Institute University of Antwerp Antwerp Belgium

Malia Surgery Kastelli HC Heraklio Greece

RCSI Department of General Practice 123 St Stephens Green Dublin 2 Ireland

Research Education Development and Innovation Primary Health Care Region Västra Götaland Sandared Sweden

Research Leader Antibiotic Centre for Primary Care Department of General Practice University of Oslo Oslo Norway

Research Unit for General Practice Department of Public Health University of Copenhagen Copenhagen Denmark

School of Primary Care Population Sciences and Medical Education Faculty of Medicine University of Southampton Southampton UK

Section and Research Unit of General Practice Department of Public Health University of Copenhagen Copenhagen Denmark

The Nuffield Department of Primary Care Health Sciences University of Oxford Oxford UK

University Institute in Primary Care Research Jordi Gol Via Roma Health Centre Barcelona Spain

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010844
003      
CZ-PrNML
005      
20230801132642.0
007      
ta
008      
230718s2023 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10198-022-01521-2 $2 doi
035    __
$a (PubMed)36131214
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Li, Xiao $u Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Campus Drie Eiken, room D.S.221, Universiteitsplein 1, 2610, Antwerp, Belgium. xiao.li@uantwerpen.be $1 https://orcid.org/0000000219181791
245    10
$a Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries / $c X. Li, J. Bilcke, AW. van der Velden, R. Bruyndonckx, S. Coenen, E. Bongard, M. de Paor, S. Chlabicz, M. Godycki-Cwirko, N. Francis, R. Aabenhus, HC. Bucher, A. Colliers, A. De Sutter, A. Garcia-Sangenis, D. Glinz, NJ. Harbin, K. Kosiek, M. Lindbæk, C. Lionis, C. Llor, R. Mikó-Pauer, R. Radzeviciene Jurgute, B. Seifert, PD. Sundvall, P. Touboul Lundgren, N. Tsakountakis, TJ. Verheij, H. Goossens, CC. Butler, P. Beutels, ALIC4Etrial investigators
520    9_
$a BACKGROUND: Oseltamivir is usually not often prescribed (or reimbursed) for non-high-risk patients consulting for influenza-like-illness (ILI) in primary care in Europe. We aimed to evaluate the cost-effectiveness of adding oseltamivir to usual primary care in adults/adolescents (13 years +) and children with ILI during seasonal influenza epidemics, using data collected in an open-label, multi-season, randomised controlled trial of oseltamivir in 15 European countries. METHODS: Direct and indirect cost estimates were based on patient reported resource use and official country-specific unit costs. Health-Related Quality of Life was assessed by EQ-5D questionnaires. Costs and quality adjusted life-years (QALY) were bootstrapped (N = 10,000) to estimate incremental cost-effectiveness ratios (ICER), from both the healthcare payers' and the societal perspectives, with uncertainty expressed through probabilistic sensitivity analysis and expected value for perfect information (EVPI) analysis. Additionally, scenario (self-reported spending), comorbidities subgroup and country-specific analyses were performed. RESULTS: The healthcare payers' expected ICERs of oseltamivir were €22,459 per QALY gained in adults/adolescents and €13,001 in children. From the societal perspective, oseltamivir was cost-saving in adults/adolescents, but the ICER is €8,344 in children. Large uncertainties were observed in subgroups with comorbidities, especially for children. The expected ICERs and extent of decision uncertainty varied between countries (EVPI ranged €1-€35 per patient). CONCLUSION: Adding oseltamivir to primary usual care in Europe is likely to be cost-effective for treating adults/adolescents and children with ILI from the healthcare payers' perspective (if willingness-to-pay per QALY gained > €22,459) and cost-saving in adults/adolescents from a societal perspective.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a dítě $7 D002648
650    _2
$a lidé $7 D006801
650    _2
$a analýza nákladů a výnosů $7 D003362
650    _2
$a oseltamivir $x terapeutické užití $7 D053139
650    12
$a chřipka lidská $x farmakoterapie $7 D007251
650    _2
$a kvalita života $7 D011788
650    12
$a virové nemoci $7 D014777
650    _2
$a kvalitativně upravené roky života $7 D019057
650    _2
$a primární zdravotní péče $7 D011320
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bilcke, Joke $u Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Campus Drie Eiken, room D.S.221, Universiteitsplein 1, 2610, Antwerp, Belgium $1 https://orcid.org/0000000157205291
700    1_
$a van der Velden, Alike W $u Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands $1 https://orcid.org/0000000294432837
700    1_
$a Bruyndonckx, Robin $u Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BIOSTAT), Data Science Institute (DSI), Hasselt University, Hasselt, Belgium $u Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium $1 https://orcid.org/0000000242172869
700    1_
$a Coenen, Samuel $u Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium $u Department of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium $1 https://orcid.org/0000000212388052
700    1_
$a Bongard, Emily $u The Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK $1 https://orcid.org/0000000159576280
700    1_
$a de Paor, Muirrean $u RCSI Department of General Practice, 123 St Stephens Green, Dublin 2, Ireland
700    1_
$a Chlabicz, Slawomir $u Department of Family Medicine, Medical University of Bialystok, Białystok, Poland $1 https://orcid.org/0000000150224588
700    1_
$a Godycki-Cwirko, Maciek $u Centre for Family and Community Medicine, Medical University of Lodz, Lodz, Poland
700    1_
$a Francis, Nick $u School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK $1 https://orcid.org/0000000189397312
700    1_
$a Aabenhus, Rune $u Section and Research Unit of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000193542236
700    1_
$a Bucher, Heiner C $u Division of Infectious Diseases and Hospital Hygiene, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
700    1_
$a Colliers, Annelies $u Department of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium
700    1_
$a De Sutter, An $u Department of Public Health and Primary Care (Centre for Family Medicine), Gent University, Gent, Belgium $1 https://orcid.org/0000000225408307
700    1_
$a Garcia-Sangenis, Ana $u University Institute in Primary Care Research Jordi Gol, Via Roma Health Centre, Barcelona, Spain $1 https://orcid.org/0000000266896466
700    1_
$a Glinz, Dominik $u Department of Clinical Research, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland $1 https://orcid.org/0000000335098186
700    1_
$a Harbin, Nicolay J $u Department of General Practice, Antibiotic Center for Primary Care, Institute of Health and Society, University of Oslo, Oslo, Norway $1 https://orcid.org/0000000230056908
700    1_
$a Kosiek, Katarzyna $u Family Doctors' Clinic, Lodz, Poland
700    1_
$a Lindbæk, Morten $u Research Leader Antibiotic Centre for Primary Care, Department of General Practice, University of Oslo, Oslo, Norway
700    1_
$a Lionis, Christos $u General Practice and Primary Health Care at the School of Medicine, University of Crete, Crete, Greece $1 https://orcid.org/0000000293242839
700    1_
$a Llor, Carl $u University Institute in Primary Care Research Jordi Gol, Via Roma Health Centre, Barcelona, Spain $u Research Unit for General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/000000016644717X
700    1_
$a Mikó-Pauer, Réka $u DRC Drug Research Center LLC, Balatonfüred, Hungary
700    1_
$a Radzeviciene Jurgute, Ruta $u FDC Mano šeimos gydytojas, Klaipeda, Lithuania
700    1_
$a Seifert, Bohumil $u Institute of General Practice, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $1 https://orcid.org/0000000268818840 $7 xx0017737
700    1_
$a Sundvall, Pär-Daniel $u General Practice/Family Medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden $u Research, Education, Development and Innovation, Primary Health Care, Region Västra Götaland, Sandared, Sweden $1 https://orcid.org/000000019889509X
700    1_
$a Touboul Lundgren, Pia $u Département de Santé Publique, Hôpital de l'Archet, Nice, France
700    1_
$a Tsakountakis, Nikolaos $u Malia Surgery, Kastelli HC, Heraklio, Greece
700    1_
$a Verheij, Theo J $u Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands
700    1_
$a Goossens, Herman $u Department of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium
700    1_
$a Butler, Christopher C $u The Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
700    1_
$a Beutels, Philippe $u Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Campus Drie Eiken, room D.S.221, Universiteitsplein 1, 2610, Antwerp, Belgium $1 https://orcid.org/0000000150343595
710    2_
$a ALIC4Etrial investigators
773    0_
$w MED00007432 $t The European journal of health economics : HEPAC : health economics in prevention and care $x 1618-7601 $g Roč. 24, č. 6 (2023), s. 909-922
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36131214 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132638 $b ABA008
999    __
$a ok $b bmc $g 1963328 $s 1197109
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 24 $c 6 $d 909-922 $e 20220922 $i 1618-7601 $m The European journal of health economics $n Eur J Health Econ $x MED00007432
GRA    __
$a grant HEALTH-F3-2013-602525 $p European Commission
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Archiving options